RPS6KA1 and melanoma: Apart from directly targeting Cdc25 and thereby activating Cdk1, active RSK signalling can moreover weaken the G2 DNA damage checkpoint in malignant melanoma by inhibitory phosphorylation of its central checkpoint kinase Chk1 [19].